Ono Pharmaceutical

Ono Pharmaceutical, a Pharmaceutical Preparation Manufacturing company based in Japan, reported its latest emissions data for 2024. The company's Scope 1 emissions were 7,700,000 kg CO2e, and Scope 2 (market-based) emissions were 9,800,000 kg CO2e. For Scope 3, categories reported include business travel at 4,800,000 kg CO2e, employee commute at 800,000 kg CO2e, upstream leased assets at 1,700,000 kg CO2e, waste generated in operations at 300,000 kg CO2e, fuel and energy-related activities at 3,000,000 kg CO2e, end-of-life treatment of sold products at 200,000 kg CO2e, and upstream transportation and distribution at 400,000 kg CO2e. There was no Scope 3 data for purchased goods and services in 2024. In 2023, the company's Scope 1 emissions were 6,700,000 kg CO2e, Scope 2 (market-based) emissions were 16,000,000 kg CO2e, and total Scope 3 emissions were 101,900,000 kg CO2e.

Ono Pharmaceutical has set several climate commitments. The company aims to achieve carbon neutrality for its own operations (Scope 1 and 2) by FY2025, using carbon offsets. It has brought forward its target of zero greenhouse gas emissions for the company itself (Scope 1 and 2) to FY2035 from an initial target of FY2050. Furthermore, the company commits to reducing absolute Scope 1 and 2 GHG emissions by 55% by FY2030 and 100% by FY2050, from a FY2017 base year. For Scope 3, Ono Pharmaceutical commits to reducing absolute GHG emissions by 30% by FY2030 and 60% by FY2050, also from a FY2017 base year. These targets are verified by the Science Based Targets initiative (SBTi) as consistent with keeping warming to 1.5°C.